Hims & Hers Health Inc. Stock News

New York, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- GraniteShares, a one of the leading issuer of exchange-traded funds (ETFs), today announced the launch of two new additions to its growing YieldBOOST ™ family, offering investors additional ways to access income opportunities across high-growth and highly followed segments of the equity market. Ticker Fund Underlying Company RTYY GraniteShares Yie...

The regulatory changes surrounding the weight loss treatment industry are having a large impact on Hims & Hers (HIMS 1.83%) stock.

Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product offerings and logistics, driving subscriber and revenue growth, despite near-term margin compression and increased capital expenditures. The upcoming Zava acquisition and potential regulatory changes...

Several big-name stocks just announced notable increases to their share buyback programs. These actions signal confidence, indicating that these companies' management teams may see value in their stocks.

Hims & Hers maintains its long-term Buy rating, despite recent stock volatility and slower subscriber growth. HIMS continues to expand its platform beyond GLP-1s, investing heavily in verticalization and new offerings like Labs via Quest Diagnostics. Short-term free cash flow growth will be slower due to increased capex, but management guides for $2.3B revenue in 2025 and $6.5B by 2030.

Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie NYSE: ABBV, Eli Lilly NYSE: LLY, Pfizer NYSE: PFE, and Merck NYSE: MRK—and their lineup of game-changing drugs—receive the lion's share of attention.

Oddity, the maker of Il Makiage and Spoiled Child, launched its third brand Methodiq, a telehealth platform for medical skincare. Methodiq will offer 28 new products, including creams, supplements and cosmetics, that address acne, hyperpigmentation and eczema and range in price from about $29 to around $59.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company,” NYSE: HIMS), the leading health and wellness platform, today announced that its Board of Directors has authorized a share repurchase program of up to $250 million of outstanding Class A common stock over the next three years. This new program follows the successful completion of the Company's prior $100 mi...